These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33221461)

  • 1. Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients.
    Aitmehdi R; Arnaud L; Francès C; Senet P; Monfort JB; de Risi-Pugliese T; Barbaud A; Cohen-Aubart F; Haroche J; Pha M; Hie M; Le Guern V; Costedoat-Chalumeau N; Mékinian A; Fain O; Mathian A; Amoura Z; Chasset F
    J Am Acad Dermatol; 2021 Apr; 84(4):1171-1174. PubMed ID: 33221461
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
    Wu EY; Schanberg LE; Wershba EC; Rabinovich CE
    Lupus; 2017 May; 26(6):646-649. PubMed ID: 27837194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
    Fennira F; Chasset F; Soubrier M; Cordel N; Petit A; Francès C
    J Am Acad Dermatol; 2016 Jun; 74(6):1248-51. PubMed ID: 27185425
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
    Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
    Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus.
    Kuhn A; Specker C; Ruzicka T; Lehmann P
    J Am Acad Dermatol; 2002 Apr; 46(4):600-3. PubMed ID: 11907517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lenalidomide in refractory lupus pernio.
    Dalm VA; van Hagen PM
    JAMA Dermatol; 2013 Apr; 149(4):493-4. PubMed ID: 23715134
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus.
    Klein A; Vogt T; Wenzel SM; Fleck M; Landthaler M
    Australas J Dermatol; 2011 Feb; 52(1):43-7. PubMed ID: 21332692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
    Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
    Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Systemic therapy of cutaneous lupus erythematosus].
    Ochsendorf F
    J Dtsch Dermatol Ges; 2004 Mar; 2(3):229-30; author reply 230. PubMed ID: 16281642
    [No Abstract]   [Full Text] [Related]  

  • 10. A case of herpes zoster during pimecrolimus use for the treatment of subacute cutaneous lupus erythematosus.
    Tatlican S; Eren C; Atacan D; Dalgic U; Canpolat F; Eskioglu F
    J Dermatolog Treat; 2010 Sep; 21(5):322-3. PubMed ID: 19832287
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate.
    Böhm L; Uerlich M; Bauer R
    Dermatology; 1997; 194(3):307-8. PubMed ID: 9187859
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus.
    Mazgaj M; Picard-Dahan C; Deschamps L; Marinho E; Estève E; Descamps V
    Int J Dermatol; 2020 Apr; 59(4):e118-e120. PubMed ID: 31957866
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
    Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
    Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide-induced tubulointerstitial nephritis in Hodgkin lymphoma.
    Dinh A; Palmer MB; Svoboda J; Hogan JJ
    Leuk Lymphoma; 2019 Dec; 60(12):3084-3086. PubMed ID: 31125280
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
    Ezra N; Jorizzo J
    Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological therapies in the treatment of cutaneous lupus erythematosus.
    Presto JK; Hejazi EZ; Werth VP
    Lupus; 2017 Feb; 26(2):115-118. PubMed ID: 27687023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.
    Thomson KF; Goodfield MJ
    J Dermatolog Treat; 2001 Sep; 12(3):145-7. PubMed ID: 12243705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the management of cutaneous lupus erythematosus.
    Callen JP
    Br J Dermatol; 2004 Oct; 151(4):731-6. PubMed ID: 15491411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
    Sherman MA; Srinivasalu H; Kirkorian AY; Cardis MA
    Arthritis Rheumatol; 2023 Jan; 75(1):120. PubMed ID: 35997717
    [No Abstract]   [Full Text] [Related]  

  • 20. [Lenalidomide desensitization in a patient with 5q- syndrome].
    Boudin L; Patient M; Roméo E; Bladé JS; de Jauréguiberry JP
    Bull Cancer; 2017 Sep; 104(9):814-816. PubMed ID: 28778340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.